公开(公告)号：WO2014132063A1

公开(公告)日：2014-09-04

申请号：PCT/GB2014/050583

申请日：2014-02-27

Applicant: ALCYOMICS LTD ,  UNIVERSITY OF NEWCASTLE UPON TYNE

Inventor： LOVAT, Penny ,  HILL, David ,  DICKINSON, Anne ,  AHMED, Shaheda

IPC: C12N5/071 ,  A61B5/00 ,  G01N33/50

CPC classification number: G01N33/94 ,  A61B5/411 ,  A61B5/445 ,  C12N5/0698 ,  C12N2502/094 ,  C12N2502/1323 ,  C12N2533/54 ,  G01N33/5044 ,  G01N33/5047 ,  G01N33/505 ,  G01N33/5064 ,  G01N33/5082 ,  G01N2800/24 ,  G09B23/28

Abstract: A three dimensional (3-D) model comprising a scaffold and autologous skin cells, the invention also provides methods of predicting immunogenicity and hypersensitivity or allergic or adverse immune reactions to potential therapeutic compounds, biologies, cosmetics and chemical sensitizers using the 3-D model of skin cells. The methods provide an in vitro assay employing autologous blood derived cells in the 3-D skin equivalent model and is of particular utility in the identification and prediction of skin sensitizers and in particular agents that may cause allergic contact dermatitis. The assay of the present invention provides inter alia methods of screening library compounds for sensitizing activity, identifying optimal therapeutics, especially but not exclusively, monoclonal antibodies and kits therefor.

Abstract translation: 包括支架和自体皮肤细胞的三维（3-D）模型，本发明还提供使用3-D模型预测免疫原性和对潜在的治疗化合物，生物制品，化妆品和化学敏化剂的过敏或过敏或不良免疫反应的方法 的皮肤细胞。 该方法提供了在3-D皮肤等效模型中使用自体血液来源的细胞的体外测定，并且在鉴定和预测皮肤敏化剂，特别是可能引起过敏性接触性皮炎的试剂中尤其有用。 本发明的测定特别提供了筛选文库化合物以增强活性，鉴定最佳治疗剂的方法，特别但非排他地，单克隆抗体及其试剂盒。

公开(公告)号：WO2016075440A1

公开(公告)日：2016-05-19

申请号：PCT/GB2015/053347

申请日：2015-11-05

Applicant: UNIVERSITY OF NEWCASTLE UPON TYNE

Inventor： LABUS, Marie ,  LOVAT, Penny ,  ELLIS, Robert

IPC: G01N33/574

CPC classification number: G01N33/5743 ,  G01N2800/20 ,  G01N2800/52 ,  G01N2800/56 ,  G01N2800/7028

Abstract: The present invention relates inter alia to therapeutic agents for use in the treatment of melanoma, methods of diagnosing an increased risk of metastasis in a subject suffering from melanoma, methods of treating such subjects, diagnostic assays and kits. More particularly, in certain embodiments the invention relates to identifying whether a subject suffering from melanoma has an increased risk of metastasis by determining the expression of Ambra-1 and Loricrin in a tissue sample obtained from the subject.

Abstract translation: 本发明特别涉及用于治疗黑素瘤的治疗剂，诊断患有黑素瘤的受试者的转移风险增加的方法，治疗这些受试者的方法，诊断测定和试剂盒。 更具体地，在某些实施方案中，本发明涉及通过测定从受试者获得的组织样品中Ambra-1和Loricrin的表达来鉴定患有黑素瘤的受试者是否具有增加的转移的风险。